DS
Therapeutic Areas
Xeris Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Gvoke (glucagon) | Severe Hypoglycemia | Approved |
| Gvoke PFS | Pediatric Severe Hypoglycemia | Approved |
| Keveyis (dichlorphenamide) | Primary Periodic Paralysis | Approved |
| Recorlev (levoketoconazole) | Endogenous Cushing's Syndrome | Approved |
| XP-8121 (Liquid Glucagon) | Bi-hormonal Pump for Diabetes | Phase 2 |
| XP-8121 | Congenital Hyperinsulinism | Preclinical/Phase 1 |
| Ogluo | Severe Hypoglycemia | Approved |
Leadership Team at Xeris Pharmaceuticals
PR
Paul R. Edick
Chairman and Chief Executive Officer
BM
Barry M. Deutsch
Chief Financial Officer
JP
John P. Schmid
Chief Business Officer
KE
Kenneth E. Johnson
Chief Scientific Officer
SP
Steven Prestrelski
Chief Technology Officer and Co-Founder
RD
R. Drew Nordlicht
Chief Commercial Officer
BP
Beth P. Hecht
Chief Legal Officer and Corporate Secretary
BJ
Brett J. Zbar
Chief Operating Officer
TW
Timothy Walbert
Director
GA
Garry A. Neil
Director